^(131)I-G250McAb治疗荷人肾透明细胞癌裸鼠的实验研究

Effect of 131I-labeled G250 monoclonal antibody on the nude mice bearing human renal cancer

目的:研究131I标记的抗肾癌相关抗原G250单克隆抗体(131I-G250McAb)在荷人肾透明细胞癌裸鼠体内的分布,探讨应用131I-G250单克隆抗体治疗实验性人肾癌的可行性和有效性。方法:将标记好的131I-G250单克隆抗体1mL/只(3.7MBq)静脉注射荷人肾癌裸鼠体内,后分批处死裸鼠,测定每克组织摄取占放射性计数百分比(%ID/g),肿瘤与其他脏器的单位质量放射性比值(T/NT)获得131I-G250单克隆抗体在体内的分布特点;取16只裸鼠根据性别、体质量和肿瘤体积大小随机分配到A、B、C和D 4个不同的处理组中,1个月后测量各组不同时点肿瘤体积大小。结果:131I-G250抗体分布在肿瘤组织中始终处于较高浓度,T/NT最大值为5(肿瘤/肌肉),48h后平均每克肿瘤组织%ID/g达最大值为8.61±0.29。30d后肿瘤体积A、B、C和D组分别为(2.04±0.18)、(0.77±0.04)、(1.85±0.11)和(1.81±0.22)cm3,B组肿瘤体积与其他3组比较差异有统计学意义,F=76.14,P<0.05。结论:用131I标记G250单克隆抗体在实验动物体内的肿瘤部位存在特异的浓聚并能有效抑制肿瘤的生长。

OBJECTIVE：To study the distributions of 131I-G250McAb in nude mice bearing human renal cancer,and explore the feasibility and efficacy of 131I-G250 in treating experimental human renal cancer.METHODS： After the animal models were established,1 mL131I-G250（3.7MBq） was injected through their tail veils.Radioactivity in tissue was measured at certain time after injection.The distribution of 131I-G250 was measured by comparing the radioactivity of tumor with the radioactivity of non-tumor（T/NT）.Sixteen nude mices were divided into four groups（A,B,C,D） according to gender,weight and the tumor volume.After injection,tumor growth was monitored for one month.RESULTS： More radioactivity accumulated in the tumor and the highest T/NT radioactivity ratio was 5.0（tumor/muscle）.The percentage of injected dose per gram（%ID/g）reached the peak with 8.61±0.29 at 48h after injection.One month later,the volume of the tumor in 131I-G250 group was（0.77±0.04） cm3,while in 0.9%NaCl group was（2.04±0.18）,Na131I group and G250 I group were（1.85±0.11） and（1.81±0.22） cm3 respectively.The volume of the tumor in B group was significantly reduced compared to other three groups（F=76.14,P0.05）.CONCLUSION： The results demonstrate that 131I-G250 can specifically accumulate in the tumor and effectively inhibit its growth.